Contineum Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule drugs for neuroscience, inflammation, and immunology indications with high unmet need. Its pipeline is built around internally discovered candidates, including PIPE-791, an LPA1 receptor antagonist studied for idiopathic pulmonary fibrosis and chronic pain. The company focuses on clinically validated biological targets rather than commercial products today.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -16 | — |
| Q2 2025 | 0 | — | -16 | — |
| Q3 2025 | 0 | — | -12.8 | — |
| Q4 2025 | 0 | — | -15.2 | — |
| Q1 2026 | 0 | — | -14.5 | — |
| Q2 2026 | 0 | — | -15.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: NioCorp Developments Ltd. (NB), OneSpan Inc. (OSPN), OrthoPediatrics Corp. (KIDS), AlTi Global, Inc. (ALTI), Altimmune, Inc. (ALT), The Oncology Institute, Inc. (STLN)